MedTrace Logo

Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment

NCT03515915 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-05-11

No results posted yet for this study

Summary

Panobinostat is a potent oral histone deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation. It was recently approved by the US Food and Drug Administration for use in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma (MM) who have received ≥ 2 prior regimens, including bortezomib and an immunomodulatory drug.

A GEP-based histone acetylation score allowing identification of MM patients with a poor prognosis and who could benefit from HDACi treatment was recently reported(Moreaux et al. BJC. 2013).

Our hypothesis is that the histone acetylation score could be promising to identify MM patients who could benefit from treatment with HDACi and the development of personalized treatment.

Conditions

  • Patients With Recurrent or Refractory Multiple Myeloma

Sponsors & Collaborators

  • Poitiers University Hospital

    collaborator OTHER

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • JEROME MOREAUX, PhD · University Hospital, Montpellier

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-23
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03515915 on ClinicalTrials.gov